Source: Eur Respir J 2004; 24: 947-953
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Lode H., Eller J., Linnhoff A., Ioanas M., the Evaluation of.... Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur Respir J 2004; 24: 947-953

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002 Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results Source: Eur Respir J 2012; 40: 17-27 Year: 2012 Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD Source: Eur Respir J 2009; 34: 1066-1071 Year: 2009 Antibiotic treatment and prevention of exacerbations of COPD Source: Eur Respir Monogr 2013; 60: 96-106 Year: 2013 Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD Year: 2003 Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001 Antibiotic treatment and prophylaxis Source: Annual Congress 2006 - Infections and chronic obstructive lung diseases Year: 2006 The effect of 3 months oral clarithromycin on sputum bacterial colonization in stable moderate- to- severe chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001 Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002 Prolonging the interval to the next acute exacerbations Source: Annual Congress 2005 - Infection and acute exacerbation of COPD: what do we know? Year: 2005 Why short-term antibiotic use in AECB may influence long-term outcomes Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI Year: 2005 5-day moxifloxacin versus 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis: a cost-minimization analysis Source: Eur Respir J 2003; 22: Suppl. 45, 336s Year: 2003 Five-day telithromycin is as effective as 10-day clarithromycin in the treatment of acute exacerbations of chronic bronchitis Source: Eur Respir J 2003; 22: Suppl. 45, 351s Year: 2003 Short and long-term outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): The MOSAIC study Source: Eur Respir J 2003; 22: Suppl. 45, 566s Year: 2003 Comparison of the efficacy of azythromycin and roxithromycin in the treatment of acute purulent exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 138s Year: 2001 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003 Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD Source: Eur Respir J 2009; 33: 282-288 Year: 2009 The effect of long-term macrolides therapy for acute exacerbation of chronic obstructive pulmonary disease: A meta-analysis Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Greatest International ANti-infective Trial (GIANT) – the German cohort: moxifloxacin treatment provides short- and long-term benefits in AECB patients Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006